Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Solid Tumors 1Solid Tumor 1Neuroblastoma 1Neoplasms 1Diarrhea 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Cefpodoxime × Clear all
NCT00644696 2017-07-06

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

University of Michigan Rogel Cancer Center

Phase 1 Completed
18 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡